M. Kudrimoti, A. Curtis, S. Azawi
May 17, 2017
Citations
0
Influential Citations
14
Citations
Quality indicators
Journal
Biotechnology Reports
Abstract
Highlights • Dusquetide was well-tolerated during treatment and throughout the 12-month follow-up.• Dusquetide did not interfere with tumor treatment.• Dusquetide treated groups had less mortality that placebo treated groups through the 12-month follow-up.• Dusquetide treated groups had fewer “non-fungal” infections than placebo treated groups.